JAMA Dermatology

<jats:sec id="ab-doi240013-4"><jats:title>Importance</jats:title><jats:p>Rates of physician-diagnosed eczema have been increasing among older adults, but little is known regarding the pathophysiologic processes and best treatments in this subgroup. Preliminary data suggest that medications—antihypertensive medications in particular—may contribute to eczematous dermatitis; however, there are limited population-based data on the proportion of eczematous dermatitis diagnoses among older adults that may be attributed to antihypertensive drugs.</jats:p></jats:sec><jats:sec id="ab-doi240013-5"><jats:title>Objectives</jats:title><jats:p>To determine whether antihypertensive drug use is associated with eczematous dermatitis in older adults.</jats:p></jats:sec><jats:sec id="ab-doi240013-6"><jats:title>Design, Settings, and Participants</jats:title><jats:p>This was a longitudinal cohort study of a population-based sample of individuals 60 years and older without a diagnosis of eczematous dermatitis at baseline. It was conducted at primary care practices participating in The Health Improvement Network in the United Kingdom from January 1, 1994, to January 1, 2015. Data analyses were performed from January 6, 2020, to February 6, 2024.</jats:p></jats:sec><jats:sec id="ab-doi240013-7"><jats:title>Exposure</jats:title><jats:p>Exposure date by first prescription for an antihypertensive drug within each drug class.</jats:p></jats:sec><jats:sec id="ab-doi240013-8"><jats:title>Main outcome measures</jats:title><jats:p>Newly active eczematous dermatitis was based on the first date for 1 of the 5 most common eczema codes used in a previously validated algorithm.</jats:p></jats:sec><jats:sec id="ab-doi240013-9"><jats:title>Results</jats:title><jats:p>Among the total study sample of 1 561 358 older adults (mean [SD] age, 67 [9] years; 54% female), the overall prevalence of eczematous dermatitis was 6.7% during a median (IQR) follow-up duration of 6 (3-11) years. Eczematous dermatitis incidence was higher among participants receiving antihypertensive drugs than those who did not (12 vs 9 of 1000 person-years of follow-up). Adjusted Cox proportional hazard models found that participants who received any antihypertensive drugs had a 29% increased hazard rate of any eczematous dermatitis (hazard ratio [HR], 1.29; 95% CI, 1.26-1.31). When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21; 95% CI, 1.19-1.24) and calcium channel blockers (HR, 1.16; 95% CI, 1.14-1.18), and the smallest effect sizes were for angiotensin-converting enzyme inhibitors (HR, 1.02; 95% CI, 1.00-1.04) and β-blockers (HR, 1.04; 95% CI, 1.02-1.06).</jats:p></jats:sec><jats:sec id="ab-doi240013-10"><jats:title>Conclusions and Relevance</jats:title><jats:p>This cohort study found that antihypertensive drugs were associated with a small increased rate of eczematous dermatitis, with effect sizes largest for calcium channel blockers and diuretic drugs, and smallest for angiotensin-converting enzyme inhibitors and β-blockers. Although additional research is needed to understand the mechanisms underlying the association, these data could be helpful to clinicians to guide management when a patient presents with eczematous dermatitis in older age.</jats:p></jats:sec>

The epidemiology of atopic dermatitis in older adults: a population-based study in the United Kingdom.

PLoS One

Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review.

JAMA Dermatol

Chronic eczematiform eruption in the elderly.

Ann Dermatol Venereol

Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

Immunopharmacol Immunotoxicol

Pruritus in the older patient: a clinical review.

JAMA

Pruritus in elderly patients–eruptions of senescence.

Semin Cutan Med Surg

Systemic allergic dermatitis (systemic contact dermatitis) from pharmaceutical drugs: A review.

Contact Dermatitis

Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study.

J Invest Dermatol

Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers.

Development and validation of an algorithm to accurately identify atopic eczema patients in primary care electronic health records from the UK.

The diagnosis, burden and prognosis of dementia: A record-linkage cohort study in England.

Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.

Inform Prim Care

Validity of diagnostic coding within the General Practice Research Database: a systematic review.

Br J Gen Pract

Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.

Pharmacoepidemiol Drug Saf

Validation of International Classification of Diseases, Ninth Revision, codes for atopic dermatitis.

Allergy

The Read clinical classification.

Growing evidence for an association between inflammatory skin disease and chronic kidney disease.

Br J Dermatol

Using the E-value to assess the potential effect of unmeasured confounding in observational studies.

Sensitivity analysis in observational research: introducing the E-value.

Ann Intern Med

A proportional hazards model for the subdistribution of a competing risk.

J Am Stat Assoc

Intractable pruritus with chronic eczema in an elderly patient caused by long-term intake of calcium channel blocker.

Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist.

Association between atopic dermatitis and hypertension: a systematic review and meta-analysis.

Salt sensitivity of blood pressure: a scientific statement from the American Heart Association.

Hypertension

Sodium chloride is an ionic checkpoint for human TH2 cells and shapes the atopic skin microenvironment.

Sci Transl Med

Completeness and usability of ethnicity data in UK-based primary care and hospital databases.

J Public Health (Oxf)

Guidelines of care for the management of atopic dermatitis: diagnosis and assessment of atopic dermatitis.

J Am Acad Dermatol

Rates of physician-diagnosed eczema have been increasing among older adults, but little is known regarding the pathophysiologic processes and best treatments in this subgroup. Preliminary data suggest that medications-antihypertensive medications in particular-may contribute to eczematous dermatitis; however, there are limited population-based data on the proportion of eczematous dermatitis diagnoses among older adults that may be attributed to antihypertensive drugs.
To determine whether antihypertensive drug use is associated with eczematous dermatitis in older adults.
This was a longitudinal cohort study of a population-based sample of individuals 60 years and older without a diagnosis of eczematous dermatitis at baseline. It was conducted at primary care practices participating in The Health Improvement Network in the United Kingdom from January 1, 1994, to January 1, 2015. Data analyses were performed from January 6, 2020, to February 6, 2024.
Exposure date by first prescription for an antihypertensive drug within each drug class.
Newly active eczematous dermatitis was based on the first date for 1 of the 5 most common eczema codes used in a previously validated algorithm.
Among the total study sample of 1 561 358 older adults (mean [SD] age, 67 [9] years; 54% female), the overall prevalence of eczematous dermatitis was 6.7% during a median (IQR) follow-up duration of 6 (3-11) years. Eczematous dermatitis incidence was higher among participants receiving antihypertensive drugs than those who did not (12 vs 9 of 1000 person-years of follow-up). Adjusted Cox proportional hazard models found that participants who received any antihypertensive drugs had a 29% increased hazard rate of any eczematous dermatitis (hazard ratio [HR], 1.29; 95% CI, 1.26-1.31). When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21; 95% CI, 1.19-1.24) and calcium channel blockers (HR, 1.16; 95% CI, 1.14-1.18), and the smallest effect sizes were for angiotensin-converting enzyme inhibitors (HR, 1.02; 95% CI, 1.00-1.04) and β-blockers (HR, 1.04; 95% CI, 1.02-1.06).
This cohort study found that antihypertensive drugs were associated with a small increased rate of eczematous dermatitis, with effect sizes largest for calcium channel blockers and diuretic drugs, and smallest for angiotensin-converting enzyme inhibitors and β-blockers. Although additional research is needed to understand the mechanisms underlying the association, these data could be helpful to clinicians to guide management when a patient presents with eczematous dermatitis in older age.

Antihypertensive Medications and Eczematous Dermatitis in Older Adults.

Antihypertensive Medications and Eczematous Dermatitis in Older Adults

Antihypertensive Medications and Eczematous Dermatitis in Older Adults

Clinical Summary

What was studied

Key findings

Clinical implications

Related Questions